The development of new pharmacological compounds can be lengthy and very costly, with many failure risks even during later phase clinical trials. To estimate a drug’s clinical potential, information on safety, pharmacokinetic and pharmacodynamic outcomes are all paramount. Via innovative techniques, critical information on a compound’s dose-response effect can be acquired in the early clinical phase.

Please download this free white paper to read more.